ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Status: Publicly traded
Direct answer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is publicly traded on HKSE under the ticker 1541.HK.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS),...
Can you invest in ImmuneOnco Biopharmaceuticals (Shanghai) Inc.?
Yes. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. trades publicly on HKSE as 1541.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Detailed equity research is provided by MarketSnap.